Modern Diagnost. (544673)

Score breakdown: P/E: 2/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• ROCE of 38.99% indicates strong historical capital efficiency
• Low P/E of 12.96 could offer value if earnings normalize
• Healthcare diagnostics services typically have recurring, defensive demand
• Small market cap of ₹116 crore leaves room for niche growth

Concerns

• Latest quarter shows ₹0 crore sales and ₹0 crore profit, making current earnings unreliable
• Piotroski F-Score of 3/9 suggests weak financial health
• Zero sales and profit growth with zero dividend yield offers no return while waiting
• Missing data on book value, debt/equity, ROE, and promoter holding limits confidence

AI Analysis

At ₹77, Modern Diagnost. is a small healthcare diagnostics player with a market cap of ₹116 crore and a P/E of 12.96. On its face, that looks reasonably priced. But Graham taught me to judge a business by its measurable evidence, not by hope. The only bright number here is ROCE of 38.99%, which suggests the company has historically used its capital efficiently. That is the kind of signal I like to see in a service business. However, the rest of the picture is troubling. Sales growth and profit growth are both 0.00%, and the latest quarter reports sales of ₹0 crore and net profit of ₹0 crore. If that is accurate, the company currently has no earning power at all. The trailing P/E may be based on stale or non-recurring earnings. The Piotroski F-Score of 3/9 also points to financial weakness and poor operational health. I cannot calculate return on equity, book value, or debt-to-equity because the data is missing, and promoter holding is not disclosed. That leaves too many blind spots. A zero dividend yield further reduces my patience. This is not a business I can confidently buy as a going concern. It could be a turnaround if the zero quarter was a one-time disruption and operations recover, but I need proof. Until I see a quarter with real sales and profit, and a clean balance sheet, this remains a speculation, not an investment. I will wait.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer